Envista Holdings Corporation (NVST)
NYSE · Healthcare · Medical Instruments & Supplies
$23.34−0.51%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $3.7B
- P/E (trailing)
- 40.2
- Forward P/E
- 14.0
- 52-week range
- $18.77 – $30.42
- 52-week change
- +14.89%
- EPS (trailing)
- $0.58
- Analyst rating
- 2.1 Buy
- Next earnings
- Oct 28, 2026
Fiscal year to Dec 2025
- Revenue
- $2.7B (+8.32%)
- Net income
- $47.0M
- Operating margin
- 7.9%
- Diluted EPS
- $0.28
- Free cash flow
- $230M
From the company’s annual report on SEC EDGAR.
About Envista Holdings Corporation
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products. This segment offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands.
Headquarters: Brea, United States · 12,000 employees · envistaco.com